Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Summit Therapeutics (SMMT) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK) Keytruda in ...

Merck & Co., Inc. MRK secured a favorable recommendation from a European regulatory committee for its cancer therapy Keytruda in combination with Padcev to treat adults facing resectable ...

Phase 3 INTerpath-001 shows personalised mRNA cancer vaccine (intismeran autogene) meaningfully improves recurrence-free ...

The medicines Merck sells today grew at their usual pace. What investors spent the year repricing was everything that comes next.

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Drug major Merck & Co., Inc. ( MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending approval of ...